Association of melanoma and natalizumab therapy in the Italian MS population: a second case report.
There is debate about a possible association between natalizumab treatment and higher risk of melanoma. Here we report a case of melanoma in a patient who developed melanoma after 77 infusions of natalizumab, without known risk factors. Pharmacovigilance programs of new drugs can help to monitor adverse events in patients at risk.
Multiple Sclerosis Center, Department of Neurosciences, Ophthalmology and Genetics, University of Genoa, Genoa, Italy.
A
A
Laroni
M
M
Bedognetti
A
A
Uccelli
E
E
Capello
G L
GL
Mancardi
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D009103:Multiple Sclerosis / Q000150:complications; D000069442:Natalizumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab